Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-03-21
Schrödinger, Inc.
Schrödinger sells computational chemistry and drug-discovery workflow software and also earns collaboration, milestone, and royalty upside from partnered and proprietary programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Modeling Tool to Discovery Operating Layer
The upside depends on becoming the trusted workspace where pharma teams run AI plus physics workflows, not on selling one more modeling seat. A rerating is plausible if hosted growth holds and partner-funded asset validation arrives.

Analysis

Thesis
SDGR is a cash-rich discovery software company with asymmetric upside if LiveDesign becomes pharma’s governed workflow layer for physics+AI, because hosted software can compound faster than GAAP optics imply while partner-funded programs add royalty optionality without requiring a full biotech balance-sheet burn.
Last Economy Alignment
AI expands demand for simulation-led molecular discovery, and Schrödinger owns useful workflow and trust surfaces. But it does not own the core compute or lab bottlenecks, so internal pharma stacks and cheaper tools can still cap value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.9x (from 5 most recent analyses)
Reasoning
The upside case is not a pure drug bet. It is a quality-of-revenue rerating: hosted contracts improve durability, LiveDesign becomes the trusted collaboration layer for AI-assisted discovery, and partner-funded assets add upside without forcing heavy internal spend. That mix can support a materially higher value, but not a premium SaaS extreme, because proof of workflow control and clinical validation is still incomplete.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not solvency but proof. Schrödinger must show hosted ACV can keep growing through 2026, that products like Predictive Toxicology expand wallet share, and that at least one clinical partner validates downstream asset quality. If customers treat the company as a premium modeling tool instead of a workflow control point, pricing power and multiple expansion stay capped.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.47
They help drug companies handle a world where AI can imagine many more molecules, because their software keeps the work organized, shared, and auditable. The risk is that big pharma or cheaper AI tools capture more of the workflow and leave Schrödinger as a useful engine without owning the main customer relationship.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.13
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case